Skip Nav Destination
![]()
You do not currently have access to this content.
EZH2 Inhibitor Beneficial against Advanced Prostate Cancer
March 5, 2025
The EZH2 inhibitor mevrometostat, in combination with the androgen receptor signaling inhibitor enzalutamide, improved progression-free survival and objective response rates in patients with metastatic castration-resistant prostate cancer compared with enzalutamide alone.
RSS Feeds